Fulltext

Cognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial

Urben, Sébastien ; Baumann, Pierre ; Barcellona, Sandra ; Hafil, Muriel ; Preuss, Ulrich ; Peter-Favre, Claire ; Clarke, Stéphanie ; Halfon, Olivier ; Holzer, Laurent

In: Psychiatric Quarterly, 2012, vol. 83, no. 3, p. 311-324

Zum persönliche Liste hinzufügen
    Titel
    • Cognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial
    Autor
    • Urben, Sébastien. Unité de Recherche, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (SUPEA), Centre Hospitalier Universitaire Vaudois (CHUV), Route du Bugnon 25A, 1011, Lausanne, Switzerland
    • Baumann, Pierre. Département de Psychiatrie, CHUV, Prilly-Lausanne, Switzerland
    • Barcellona, Sandra. Centre Thérapeutique de Jour pour Adolescents, SUPEA, CHUV, Lausanne, Switzerland
    • Hafil, Muriel. Centre Thérapeutique de Jour pour Adolescents, SUPEA, CHUV, Lausanne, Switzerland
    • Preuss, Ulrich. Kinder und Jugendpsychiatrische Poliklinik, Bern, Switzerland
    • Peter-Favre, Claire. Division de Neuropsychologie, CHUV, Lausanne, Switzerland
    • Clarke, Stéphanie. Division de Neuropsychologie, CHUV, Lausanne, Switzerland
    • Halfon, Olivier. SUPEA, CHUV, Lausanne, Switzerland
    • Holzer, Laurent. Centre Thérapeutique de Jour pour Adolescents, SUPEA, CHUV, Lausanne, Switzerland
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Psychiatric Quarterly, 2012, vol. 83, no. 3, p. 311-324. Springer US; http://www.springer-ny.com
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:319058
    Summary
    Twenty-three adolescents with psychotic disorders, aged from 13 to 18years, participated in a 12-week open label trial (17 adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global Impression and Positive and Negative Symptom Scale (P's≤0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed on one executive function (P=0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction between quetiapine doses (>300mg/day or <300mg/day) and time, where lower doses showed more improvement in verbal short-term memory (P=0.048), inhibition abilities (P=0.038) and positive symptoms (P=0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12weeks of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition abilities and verbal short-term memory) and on positive symptoms